跳轉至內容
Merck
全部照片(1)

重要文件

SML2324

Sigma-Aldrich

NLX-112 hydrochloride

≥98% (HPLC)

同義詞:

(3-Chloro-4-fluorophenyl)[4-fluoro-4-[[[(5-methyl-2-pyridinyl)methyl]amino]methyl]-1-piperidinyl]methanone hydrochloride, Befiradol hydrochloride, F13640 hydrochloride

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C20H22ClF2N3O · xHCl
CAS號碼:
分子量::
393.86 (free base basis)
分類程式碼代碼:
12352200
NACRES:
NA.77
暫時無法取得訂價和供貨情況

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

FC2(CCN(CC2)C(=O)c3cc(c(cc3)F)Cl)CNCc1ncc(cc1)C

InChI

1S/C20H22ClF2N3O/c1-14-2-4-16(25-11-14)12-24-13-20(23)6-8-26(9-7-20)19(27)15-3-5-18(22)17(21)10-15/h2-5,10-11,24H,6-9,12-13H2,1H3

InChI 密鑰

PKZXLMVXBZICTF-UHFFFAOYSA-N

生化/生理作用

NLX-112 (also known as befiradol or F13640) is a highly selective 5-HT1A receptor full agonist with >1000-fold selectivity compared to other types of receptors. It has been investigated for the treatment of Parkinson′s disease patients who exhibit L-DOPA-induced dyskinesia
Serotonin 5-HT1A receptor full agonist

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Andrew C McCreary et al.
Neuropharmacology, 105, 651-660 (2016-01-19)
Although l-DOPA alleviates the motor symptoms of Parkinson's disease (PD), it elicits troublesome l-DOPA-induced dyskinesia (LID) in a majority of PD patients after prolonged treatment. This is likely due to conversion of l-DOPA to dopamine as a 'false neurotransmitter' from
Adrian Newman-Tancredi et al.
The Journal of pharmacy and pharmacology, 69(9), 1178-1190 (2017-06-15)
NLX-112 (befiradol, F13640) is a selective serotonin 5-HT1A receptor agonist. Although it has been tested in vivo, little has been reported on its in vitro signal transduction profile. NLX-112 was tested on G-protein activation, inhibition of adenylyl cyclase, ERK1/2 phosphorylation (pERK)
H Iderberg et al.
Experimental neurology, 271, 335-350 (2015-06-04)
L-DOPA is the gold-standard treatment for Parkinson's disease (PD), but induces troublesome dyskinesia after prolonged treatment. This is associated with the 'false neurotransmitter' conversion of L-DOPA to dopamine by serotonin neurons projecting from the raphe to the dorsal striatum. Reducing

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務